0001062993-23-016695.txt : 20230817
0001062993-23-016695.hdr.sgml : 20230817
20230817160832
ACCESSION NUMBER: 0001062993-23-016695
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230815
FILED AS OF DATE: 20230817
DATE AS OF CHANGE: 20230817
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Geist William
CENTRAL INDEX KEY: 0001832210
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-17272
FILM NUMBER: 231181940
MAIL ADDRESS:
STREET 1: 900 MIDDLESEX TURNPIKE
STREET 2: C/O QUANTERIX CORPORATION
CITY: BILLERICA
STATE: MA
ZIP: 01821
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIO-TECHNE Corp
CENTRAL INDEX KEY: 0000842023
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 411427402
STATE OF INCORPORATION: MN
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: 614 MCKINLEY PL N E
CITY: MINNEAPOLIS
STATE: MN
ZIP: 55413
BUSINESS PHONE: 6123798854
MAIL ADDRESS:
STREET 1: 614 MCKINLEY PLACE NE
CITY: MINNEAPOLIS
STATE: MN
ZIP: 55413
FORMER COMPANY:
FORMER CONFORMED NAME: TECHNE CORP /MN/
DATE OF NAME CHANGE: 19920703
4
1
form4.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
X0508
4
2023-08-15
0000842023
BIO-TECHNE Corp
TECH
0001832210
Geist William
614 MCKINLEY PL N E
MINNEAPOLIS
MN
55413
0
1
0
0
PRESIDENT, PROTEIN SCIENCES
0
Common Stock
9960
D
Restricted Stock Units
Common Stock
7140
7140
D
Stock Options (Right to Buy)
94.52
2029-08-15
Common Stock
22200
22200
D
Stock Options (Right to Buy)
94.52
2029-08-15
Common Stock
29600
29600
D
Restricted Stock Units
Common Stock
3360
3360
D
Stock Options (Right to Buy)
100.39
2029-02-01
Common Stock
11936
11936
D
Stock Options (Right to Buy)
100.39
2029-02-01
Common Stock
15912
15912
D
Restricted Stock Units
2023-08-15
4
A
0
8377
0
A
Common Stock
8377
8377
D
Stock Options (Right to Buy)
84.61
2023-08-15
4
A
0
22544
0
A
2030-08-15
Common Stock
22544
22544
D
Stock Options (Right to Buy)
84.61
2023-08-15
4
A
0
30059
0
A
2030-08-15
Common Stock
30059
30059
D
Represents 6,640 shares of restricted stock for which the risk of forfeiture will lapse as to 3,320 shares on each of February 1, 2024 and February 1, 2025.
Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
Vests in full or in part on 8/15/2025 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
Options to purchase 7,400 shares vest on each of 8/15/2023, 8/15/2024, 8/51/2025 and 8/15/2026.
Options to purchase 3,980 shares vest on each of 2/1/2023 and 2/1/2024 and options to purchase 3,976 shares vest on each of 2/1/2025 and 2/1/2026.
Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
Options to purchase 7,515 shares vest on each of 8/15/2024, 8/15/2025, 8/15/2027, and 7,514 shares vest on 8/15/2026.
On November 28, 2022, the Company completed a four-for-one stock split. All common stock amounts and exercise prices in the filing relating to securities acquired prior to November 28, 2022 have been adjusted to reflect the four-for-one stock split.
/s/ Andrew Nick as Attorney-in-Fact for William Geist pursuant to Power of Attorney previously filed
2023-08-17